10 completed, 4 terminated, 3 recruiting, 2 active not recruiting. 15 Phase 1, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 7, Recruiting 3, Terminated 3, Active not recruiting 2 |
| Phase 2 | 13 | Completed 4, Terminated 4, Recruiting 3, Active not recruiting 2 |
Follow BioInvent International AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution) - Melanoma Metastatic, Melanoma of Skin | Phase 1 / Phase 2 | Active not recruiting | BioInvent International AB | 35 | 2024-12-11 | 2026-10-02 |
| BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors BI-1910, Pembrolizumab - Solid Tumors, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | BioInvent International AB | 35 | 2023-12-04 | 2025-09-19 |
| BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors BI-1607, Trastuzumab - HER2-positive Breast Cancer, HER2-positive Gastric Cancer | Phase 1 / Phase 2 | Terminated | BioInvent International AB | 18 | 2022-07-28 | 2024-12-16 |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors BT-001, Pembrolizumab [KEYTRUDA®] - Metastatic Cancer, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Terminated | Transgene | 31 | 2021-02-25 | 2025-11-21 |
| BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection, Paclitaxel 80 mg/m2 weekly - Advanced Malignancies, Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | BioInvent International AB | 250 | 2021-01-25 | 2026-09-18 |
| A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors BI1206 - Solid Tumor, Adult | Phase 1 / Phase 2 | Recruiting | BioInvent International AB | 197 | 2020-06-29 | 2026-06-25 |
| A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL BI-1206, Rituximab, Acalabrutinib - Indolent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | BioInvent International AB | 140 | 2018-05-16 | 2026-10-02 |
| BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia BI-1206 single agent dose escalation phase, Combination of BI-1206 with rituximab escalation phase, BI-1206 single agent expansion phase - B-cell Lymphoma, Chronic Lymphocytic Leukaemia | Phase 1 / Phase 2 | Completed | Cancer Research UK | 14 | 2016-10-27 | 2021-07-08 |
| A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma BI-505, High dose melphalan, Autologous stem cell transplantation - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | BioInvent International AB | 5 | 2016-05-01 | 2020-03-12 |
| A Phase II Study of BI-505 in Smoldering Multiple Myeloma BI-505 - Smoldering Multiple Myeloma | Phase 2 | Terminated | BioInvent International AB | 4 | 2013-03-01 | 2023-01-11 |
| Bioavailability Study of MLDL1278A After Subcutaneous and Intravenous Administration in Healthy Subjects MLDL1278A - Healthy | Phase 1 | Completed | BioInvent International AB | 22 | 2011-11-01 | 2012-12-11 |
| Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery TB-402, Rivaroxaban - Prophylaxis of Venous Thromboembolic Events | Phase 2 | Completed | ThromboGenics | 632 | 2011-04-01 | 2012-08-23 |
| A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER) MLDL1278A, placebo, statin, stable dose - Atherosclerosis | Phase 2 | Completed | Genentech, Inc. | 147 | 2010-03-01 | 2016-11-02 |
| A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma BI-505 - Multiple Myeloma | Phase 1 | Completed | BioInvent International AB | 35 | 2009-12-01 | 2013-03-15 |
| Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery TB-402, Enoxaparin - Total Knee Replacement Surgery | Phase 2 | Completed | ThromboGenics | 316 | 2008-12-01 | 2014-04-07 |
| Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours TB-403 - Solid Tumors | Phase 1 | Completed | BioInvent International AB | 21 | 2008-06-01 | 2022-03-16 |
| Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects - Healthy | Phase 1 | Completed | ThromboGenics | 15 | 2008-02-01 | 2014-04-07 |
| Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402 Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402 - Healthy | Phase 1 | Completed | ThromboGenics | 12 | 2008-01-01 | 2014-04-07 |
| A Phase I Study of Monoclonal Antibody TB-402 in Healthy Male Volunteers TB-402, Placebo - Healthy | Phase 1 | Completed | ThromboGenics | 56 | 2007-03-01 | 2014-04-07 |
Melanoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Multiple Myeloma (2) · Neoplasm Metastasis (2) · Atherosclerosis (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Leukemia, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, T-Cell (1) · Ovarian Neoplasms (1) · Sarcoma (1) · Smoldering Multiple Myeloma (1) · Triple Negative Breast Neoplasms (1) · Uveal Melanoma (1)
TB 402 (5) · pembrolizumab (5) · MLDL1278A (2) · Solutions (2) · Enoxaparin (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Injections (1) · Ipilimumab (1) · Melphalan (1) · Paclitaxel (1) · Rituximab (1) · Rivaroxaban (1) · TB-403 (1) · Trastuzumab (1) · acalabrutinib (1)
Denmark (7) · Spain (6) · Sweden (6) · United States (6) · Germany (5) · United Kingdom (5) · Poland (4) · Belgium (3) · Russia (3) · Bulgaria (2) · Hungary (2) · Latvia (2) · Romania (2) · Ukraine (2) · Austria (1)
Andres McAllister, PhD (2) · Thomas J Jensen, MD, PhD (2) · Alfred Garfall, MD (1) · Andres McAllister, MD, PhD (1) · Andrew Davies, Prof (1) · Darren Wilbraham, MD (1) · Dorthe Nielsen, MD, PhD (1) · Guido Tricot, MD, PhD, Prof. (1) · Joshua Lehrer-Graiwer, M.D. (1) · Lena Winstedt, PhD (1) · Markus Hansson, MD, PhD (1) · Thomas J Jensen, M.D. (1) · Ulrik Lassen, MD, PhD (1)
PMID 20637972, PMID 25712687, PMID 28158311, PMID 41071338
2015 (1), 2023 (1)